Novartis doubles down on innovation in India, eyeing R&D, clinical trials and a stronger regulatory ecosystem while moving away from traditional generics
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.